Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Sanofi Chooses Snowflake to Accelerate its AI-Powered Drug Development
09:08am, Tuesday, 02'nd Jun 2026
SAN FRANCISCO--(BUSINESS WIRE)-- #SnowflakeSummit--SNOWFLAKE SUMMIT 26 – Snowflake (NYSE: SNOW), the AI Data Cloud company, today announced at Snowflake Summit 26 that Sanofi, one of the world's lea
FDA Grants Priority Review to SNY's Filing for Gaucher Disease Drug
11:01am, Friday, 29'th May 2026
Sanofi secures FDA priority review for venglustat in GD3, setting up a November decision on a potential first U.S. therapy for neurological symptoms.
Press Release: Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease
01:00am, Thursday, 28'th May 2026
Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026. The US Food and Drug Administration (FDA) has granted priority review to the new drug ap
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
01:15pm, Friday, 22'nd May 2026
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.
Sanofi: Information concerning the total number of voting rights and shares - April 2026
12:37pm, Tuesday, 19'th May 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?
12:26pm, Tuesday, 19'th May 2026
Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.
Sanofi says rare lung disease drug outperforms standard care in trial
03:36pm, Monday, 18'th May 2026
French drugmaker Sanofi said on Monday a trial showed its rare disease therapy was better than standard care in raising levels of a key protein in patients with a genetic form of lung disease.
ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
My Top 5 Dividend Stocks For May
10:58pm, Saturday, 16'th May 2026
I highlight five dividend stocks—HTO, ES, SNY, NLY, and AMCR—trading below fair value, each with strong balance sheets and good potential growth prospects. Each stock is projected to deliver doubl
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally
01:15pm, Wednesday, 13'th May 2026
The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.
Sanofi: Great Yield And Plenty Of Upside Potential
11:08am, Monday, 11'th May 2026
Sanofi (SNY) is rated a Strong BUY, with a robust pipeline, strong FCF, and a compelling turnaround under new leadership. SNY offers a 5.5%+ dividend yield, undervalued multiples, and projected 16–2
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
01:41pm, Friday, 08'th May 2026
Denali narrows its Q1 loss and gains FDA approval for Avlayah, the first new Hunter syndrome treatment option in nearly 20 years.
Sanofi asks to pull diabetes drug out of FDA voucher program, STAT News reports
02:38pm, Wednesday, 06'th May 2026
Sanofi has asked the U.S. Food and Drug Administration to pull its diabetes drug out of the regulator's new fast-track review program, STAT News reported on Wednesday.
Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1
12:42pm, Wednesday, 06'th May 2026
The sponsorship helps expand proven Alpha-1 detection strategies, which will enable earlier patient identification DURHAM, N.C., May 6, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit organization pow
Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't?
04:44am, Thursday, 30'th Apr 2026
A significant financing deal with Blackstone underscores that the Teva of today isn't the Teva of the past.
